Tech Company Financing Transactions
Kaleido Biosciences Funding Round
Abu Dhabi Investment Authority, Fidelity Management & Research Company and Flagship Pioneering invested in a $101 million Series C capital raise for Kaleido Biosciences. The round was announced on 6/26/2018.
Transaction Overview
Company Name
Announced On
6/26/2018
Transaction Type
Venture Equity
Amount
$101,000,000
Round
Series C
Investors
Proceeds Purpose
Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Hayden Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Kaleido is dedicated to leading a revolution in health. It all starts with the microbiome. In the last ten years, science has revealed the microbiome to be one of the most diverse, powerful organs in the body. At Kaleido, we are pioneering new ways to unlock its power to enable the body to treat disease and heal itself.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Bonney
Chief Executive Officer
Alison Lawton
Chief Financial Officer
William Duke
Chief Medical Officer
Katharine Knobil
Chief Scientific Officer
Johan van Hylckama Vlieg
Co-Founder
Geoffrey von Maltzahn
VP - Bus. Development
Clare Fisher
VP - General Counsel
Jerald Korn
Browse more venture capital transactions:
Prev: 6/26/2018: PolicyBazaar venture capital transaction
Next: 6/26/2018: MeetMindful venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs